


# Corporate Fact Sheet Report



“Ingen” is a medical device manufacturing development company that has launched an innovative line of disposable respiratory products that are focused for the emerging growth-oriented home healthcare market. With issued patents, trademarks and secured intellectual property, Ingen’s Oxyview® and Smart Nasal Cannula®, introduced in February 2010, are now the home health care oxygen market’s first oxygen tubing safety devices for patients requiring home oxygen therapy. The company received FDA Registration and Licensing through the Department of Public Health and manufactures these products in Southern California. Ingen has sold more than 120,000 units worldwide in the past few years and is now positioning to increase new distribution channels over the next several months.



## INDUSTRY OVERVIEW

Major home healthcare providers and oxygen service providers now debut the Oxyview® product line while they are seeking to capitalize on the booming aging population and the increase in home healthcare services. This market also serves younger, disabled patients who don’t require hospitalization and those recovering from acute medical conditions who only need temporary or intermittent home-based medical care.

Ingen is focused on the worldwide



healthcare market for Oxyview® as it is influenced by a number of demographic trends, including the following:

- **Growing and Aging Population:** The U.S. Census Bureau predicts that the majority of the U.S. “baby boom” population (28% of the total U.S. population) will begin to turn 65 between 2010 and 2020.
- **Consumer expectations for improved healthcare** are increasing in both developed and developing countries.
- **Technology is giving rise to new clinical therapies**, which in turn are addressing more and more medical ailments and aiding in earlier diagnosis, more efficient management and prevention of diseases.

## Stock Information



|                              |                           |
|------------------------------|---------------------------|
| <b>Business:</b>             | <i>Medical Equipment</i>  |
| <b>OTC Symbol:</b>           | <i>INGT</i>               |
| <b>Recent Price:</b>         | <i>\$0.0026 (1/09/13)</i> |
| <b>52-Week Range:</b>        | <i>\$0.06 - 0.0001</i>    |
| <b>Average Daily Volume:</b> | <i>1,064,820</i>          |
| <b>Public Float:</b>         | <i>38.1 Million</i>       |
| <b>Shares Outstanding:</b>   | <i>89.6 Million</i>       |
| <b>Market Cap:</b>           | <i>\$0.233 Million</i>    |

- Healthcare spending per capita has grown significantly across the world. In the U.S., it has increased from \$144 per capita in 1960 to almost \$4,400 in 1999. Today home healthcare equipment and services in the US have become a very important part of the healthcare industry. Oxyview® has a place in the increasing hospitalization costs that has increased the demand for low-cost alternatives, which in turn, has resulted in the emergence and growth of home healthcare facilities for the elderly, sick and disabled in the country.

## MARKETING & KEY CONCEPTS

Ingen’s Oxyview® is a pneumatic metering device that displays and confirms the oxygen flow rate near the patient. Never before has there been a device attached to the oxygen tubing that monitors oxygen flow to the patient. The Oxyview® provides safety, assurance and prevents unnecessary costs associated with malfunctions

or malpractice issues. The market potential is \$200 Million annually.

## **HIGHLY COMPETITIVE PRODUCT**

Ingen stands at a key reflex point in its history after having developed a unique solution to a growing problem in the \$55 billion per year home care medical market. Ingen is shipping product and positioning to be a global player in the months to come with a proprietary and patented respiratory product.

## **Contact:**

Ingen Technologies, Inc  
3410 La Sierra Avenue.  
Suite F507  
Riverside, CA 92503  
Phone: 951-688-7840  
Fax: 951-688-8802  
Email: [info@ingen-tech.com](mailto:info@ingen-tech.com)  
Web: [www.ingen-tech.com](http://www.ingen-tech.com)

---

### Disclaimer:

This is a paid advertisement. OTC Special Situations Report (OTC SSR) is a publication of National Financial Communications Corp. (NFC). NFC was paid twelve million restricted shares for the composition, design, and endorsement by the featured company in addition to editorial fees for the cost of dissemination. The companies featured in OTC SSR do not have to meet any specific financial criteria and are typically developmental stage companies that pose a much greater risk to investors and an investment of this type could result in a TOTAL LOSS over a period of time. Release of Liability: Through use of this advertisement (marketing piece) viewing or referencing, you agree to hold NFC Corp, its operators and associates harmless of any actions taken by you and to completely release NFC from any and all liability due to any and all losses (monetary or otherwise), or injury (monetary or otherwise) that you may incur from actions taken through information obtained in this piece. The information contained herein contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. In accordance with safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the statements contained herein that look forward in time, which include other than historical information, involve risks and uncertainties that may affect actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for the company's products or services, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, etc. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives goals, assumptions or future events or performance may be forward-looking statements. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should or might occur. This is not an offer to buy or sell securities. Information or opinions in this report are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at [www.sec.gov](http://www.sec.gov) and the National Association of Securities Dealers (NASD) at [www.nasd.com](http://www.nasd.com). The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR page. This report does not purport to be a complete study of the featured Company. Information used and statements of fact have been obtained from the featured Company and other sources, but NOT VERIFIED OR GUARANTEED by OTC SSR as to completeness or accuracy. Such information is subject to change without notice. It should be understood that there is no guarantee past performance will be indicative of future results. Opinions stated herein may be solely Geoffrey Eiten's, and not necessarily those of the featured Company. Officers, directors, and employees of NFC and anyone mentioned in this report, and members of their families may hold a position and may, from time to time, trade in these securities for their own accounts including when this report is distributed. Specific information in this regard will be furnished upon request. Trademarks are the property of their respective owners. ©2013 OTC Special Situations Report. All rights reserved. For any additional information call 781-444-6100 or see [www.otcfn.com](http://www.otcfn.com)